Learn Mode

KRYS - Krystal Biotech Inc

34

$258.32

$11.38 (4.608%)

At close: 3/31/26, 8:00 PM

Score

4.24/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

KRYS

Valuation Score

View as %

Stock Unlock

YTD

Max

Stock Profile

Market Cap

$7.55B

Industry

Biotechnology

EPS (TTM)

$6.75

P/E (TTM)

36.87

Div & Yield

FCF Payout Ratio

P/S (TTM)

19.41

P/B

6.19

Diluted Shares

30.32M

Ex-Dividend

Next Earnings

05-04

Forward P/E

30.14

Payout Ratio

P/FCF (TTM)

39.97

FCF Yield

2.50%

Earnings Yield

2.71%

52 Week Range

Score Card

Explore Scores Tab

4.24

Very Good

Krystal Biotech Inc has grown revenue at 33.95% over the past year, which is strong growth. Also, it has more cash than liabilities meaning it could use its current cash position to be completely debt-free, if it wanted to.

Valuation Model

Key Score

1.00

Very Bad

Management

5.00

Very Good

Growth

2.00

Bad

Profitability

4.00

Good

Fin. Health

1.00

Very Bad

Dividends

Analyst

1.00

Very Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

1 new filing was in the last 7 days

Filter Form Types

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-03-27 10:19:14

Form 3

Initial statement of beneficial ownership of securities - general instructions

Filed on 2026-03-06 18:26:21

Form 3

Initial statement of beneficial ownership of securities - general instructions

Filed on 2026-03-06 18:24:44

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-06 18:23:09

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-06 18:22:14

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-03-04 16:40:35

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-03-04 16:39:31

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 18:33:55

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 18:33:07

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 18:30:23

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 18:28:41

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-03-02 12:56:22

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-03-25

High:

$389.55

50.8%

Avg:

$319.36

23.6%

Low:

$217.15

-15.9%

(% change is relative to the current stock price: $258.32)

Analyst Recommendations

Go to Analyst Tab

4.35

Very Good

41%

Strong Buy (7)

53%

Buy (9)

Hold (1)

Sell (0)

Strong Sell (0)

About

Website
https://www.krystalbio.com/
Address
2100 Wharton St Ste 701, Pittsburgh PENNSYLVANIA, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1711279

Krystal Biotech, Inc. operates as a biotechnology company, which engages in developing and commercializing pharmaceutical products. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 295 full-time employees. The company went IPO on 2017-09-20. The firm is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.

IPO Date

2017-09-20

Industry

Biotechnology

Total Employees

295

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences

KRYS - Krystal Biotech Inc

34

$258.32

$11.38 (4.608%)

4.24/5

Stock Unlock

Stock Profile

Score Card

Very Good

Insider Transactions

Market News

Form SCHEDULE 13G/A

Filed on 2026-03-27 10:19:14

Form 3

Filed on 2026-03-06 18:26:21

Form 3

Filed on 2026-03-06 18:24:44

Form 4

Filed on 2026-03-06 18:23:09

Form 4

Filed on 2026-03-06 18:22:14

Form 144

Filed on 2026-03-04 16:40:35

Form 144

Filed on 2026-03-04 16:39:31

Form 4

Filed on 2026-03-03 18:33:55

Form 4

Filed on 2026-03-03 18:33:07

Form 4

Filed on 2026-03-03 18:30:23

Form 4

Filed on 2026-03-03 18:28:41

Form 144

Filed on 2026-03-02 12:56:22

Financials

Price Targets

50.8%

23.6%

-15.9%

Analyst Recommendations

About

Similar Stocks